This study demonstrates that RvD2 significantly reduces pro-inflammatory cytokines such as IL-1β, IL-6, and IL-21 in ex vivo intestinal biopsies from CD patients, including those refractories to anti-TNFα therapy. This evidence concerns the gene IL21 and Cowden disease.